ABBOTT LABORATORIES acquired Cephea Valve Technologies, Inc., a transaction announced in January 2019, structured as Purchase-option exercise (option secured 2015).
Cephea Valve Technologies, Inc. operates in Structural Heart / Medical Devices, is based in United States. Cephea Valve Technologies is a privately held medical-device company developing a less-invasive transcatheter mitral valve replacement delivered through a vein in the leg, avoiding open-heart surgery. Abbott had provided capital and secured a purchase option in 2015, and in January 2019 exercised that option to acquire the company, building on its structural-heart portfolio.
Adds a novel catheter-based mitral valve replacement to Abbott's structural-heart therapies for mitral valve disease.
Advisory firms were not disclosed for this transaction.